FDA Accepts Viridian's Veligrotug BLA For Priority Review In Thyroid Eye Disease
I'm PortAI, I can summarize articles.
Viridian Therapeutics Inc. announced that the FDA has accepted its Biologics License Application for Veligrotug, a treatment for thyroid eye disease, for priority review. The decision is expected by June 30, 2026. The application is supported by positive Phase 3 trial data, and Veligrotug has been granted breakthrough therapy designation. Viridian plans to submit a Marketing Authorisation Application to the European Medicines Agency in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments